The round was led by MSA Capital, a global private equity firm. Other participating investors include Series B Co-leads GL Ventures (venture capital arm of Hillhouse Group) and Sequoia Capital, and Series A lead VC Co-win Ventures.

Amador Bioscience, a leading partner for successful new drug development, provides global-standard translational sciences and clinical pharmacology services to clients ranging from cutting-edge biotech start-ups to multinational pharmaceutical companies.